Insider Transactions Screener
Search for and identify insider purchases or sales of company shares. The screener offers additional information and analysis on the transactions and allows users to set up alerts and receive notifications when new transactions occur.
| Ticker | Insider | Transaction Type | Ownership Type | Shares Traded | Value / Price | Filing Date |
|---|---|---|---|---|---|---|
|
SNPS
|
Roy Vallee
Director |
BUY
Grant, award, or other acquisition
|
Direct | 2,690 Added 4.64% |
-
|
Apr 02
2015 |
|
SNPS
|
Steven Walske
Director |
BUY
Grant, award, or other acquisition
|
Direct | 2,690 Added 8.16% |
-
|
Apr 02
2015 |
|
CVS
|
Lisa Bisaccia
Former EVP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 1,862 Reduced 6.05% |
$191,246
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
Andrew Sussman
EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct | 1,596 Reduced 10.27% |
$163,925
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
Helena Foulkes
EVP & President-CVS Pharmacy |
SELL
Payment of exercise price or tax liability
|
Direct | 2,394 Reduced 7.31% |
$245,888
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
Larry J Merlo
Director |
SELL
Payment of exercise price or tax liability
|
Direct | 19,944 Reduced 10.99% |
$2,048,448
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
Jonathan C Roberts
EVP & Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 4,654 Reduced 8.2% |
$478,012
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
David M Denton
EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct | 6,648 Reduced 5.59% |
$682,816
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 16,637 Added 17.49% |
$749,830
$45.07 p/Share
|
Apr 02
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 3,989 Reduced 6.06% |
$409,710
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 16,637 Reduced 21.2% |
$1,708,786
$102.71 p/Share
|
Apr 02
2015 |
|
CVS
|
J. David Joyner
President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct | 1,862 Reduced 3.15% |
$191,246
$102.71 p/Share
|
Apr 02
2015 |
|
AAPL
|
Angela J Ahrendts
Senior Vice President |
SELL
Open market or private sale
|
Direct | 25,000 Reduced 20.04% |
$3,127,000
$125.08 p/Share
|
Apr 02
2015 |
|
LGF-B
|
Jon Feltheimer
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 185,600 Reduced 11.69% |
$6,238,016
$33.61 p/Share
|
Apr 02
2015 |
|
ORCL
|
Safra Catz
Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 250,000 Added 48.78% |
$3,642,500
$14.57 p/Share
|
Apr 02
2015 |
|
CVS
|
Stephen J Gold
EVP & CIO |
BUY
Grant, award, or other acquisition
|
Direct | 5,867 Added 13.56% |
$599,959
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Lisa Bisaccia
Former EVP & Chief HR Officer |
BUY
Grant, award, or other acquisition
|
Direct | 4,889 Added 15.33% |
$499,949
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Andrew Sussman
EVP, Clinical Services |
BUY
Grant, award, or other acquisition
|
Direct | 3,422 Added 16.79% |
$349,934
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Andrew Sussman
EVP, Clinical Services |
SELL
Payment of exercise price or tax liability
|
Direct | 3,086 Reduced 20.17% |
$315,574
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Helena Foulkes
EVP & President-CVS Pharmacy |
BUY
Grant, award, or other acquisition
|
Direct | 8,556 Added 16.71% |
$874,937
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Larry J Merlo
Director |
BUY
Grant, award, or other acquisition
|
Direct | 39,115 Added 14.01% |
$3,999,900
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Jonathan C Roberts
EVP & Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct | 9,778 Added 14.27% |
$999,898
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
David M Denton
EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct | 8,556 Added 4.63% |
$874,937
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct | 2,234 Reduced 3.74% |
$228,449
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
SELL
Open market or private sale
|
Direct | 16,747 Reduced 22.55% |
$1,712,548
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct | 16,747 Added 18.4% |
$585,475
$34.96 p/Share
|
Apr 01
2015 |
|
CVS
|
Troyen A Brennan
EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct | 6,845 Added 13.5% |
$699,970
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
J. David Joyner
President and CEO |
BUY
Grant, award, or other acquisition
|
Direct | 3,422 Added 16.43% |
$349,934
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
J. David Joyner
President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct | 1,801 Reduced 3.19% |
$184,170
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Eva C Boratto
EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct | 3,911 Added 14.6% |
$399,939
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Eva C Boratto
EVP & CFO |
SELL
Payment of exercise price or tax liability
|
Direct | 1,029 Reduced 4.14% |
$105,226
$102.26 p/Share
|
Apr 01
2015 |
|
CVS
|
Thomas M Moriarty
EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct | 7,334 Added 20.25% |
$749,975
$102.26 p/Share
|
Apr 01
2015 |
|
NVDA
|
David M Shannon
EVP, CAO & Secretary |
SELL
Open market or private sale
|
Direct | 1,771 Reduced 0.51% |
$37,032
$20.91 p/Share
|
Apr 01
2015 |
|
NVDA
|
David M Shannon
EVP, CAO & Secretary |
BUY
Exercise of conversion of derivative security
|
Direct | 1,771 Added 0.51% |
$28,230
$15.94 p/Share
|
Apr 01
2015 |
|
AAPL
|
Angela J Ahrendts
Senior Vice President |
SELL
Payment of exercise price or tax liability
|
Direct | 70,929 Reduced 36.25% |
$8,812,928
$124.25 p/Share
|
Apr 01
2015 |
|
AAPL
|
Angela J Ahrendts
Senior Vice President |
BUY
Exercise of conversion of derivative security
|
Direct | 140,126 Added 41.73% |
-
|
Apr 01
2015 |
|
AAPL
|
Craig Federighi
Senior Vice President |
BUY
Exercise of conversion of derivative security
|
Direct | 53,056 Added 14.49% |
-
|
Apr 01
2015 |
|
AAPL
|
Craig Federighi
Senior Vice President |
SELL
Payment of exercise price or tax liability
|
Direct | 27,301 Reduced 8.72% |
$3,392,149
$124.25 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Mark H Md Rachesky |
BUY
Grant, award, or other acquisition
|
Direct | 959 Added 1.88% |
$31,992
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Jon Feltheimer
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 64,400 Reduced 4.16% |
$2,145,808
$33.32 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Daryl Simm
Director |
BUY
Grant, award, or other acquisition
|
Direct | 438 Added 0.64% |
$14,612
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Arthur Evrensel
Director |
BUY
Grant, award, or other acquisition
|
Direct | 397 Added 0.65% |
$13,244
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Hardwick Simmons
Director |
BUY
Grant, award, or other acquisition
|
Direct | 597 Added 0.71% |
$19,916
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Frank Giustra
Director |
BUY
Grant, award, or other acquisition
|
Direct | 263 Added 0.24% |
$8,774
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Phyllis Yaffe
Director |
BUY
Grant, award, or other acquisition
|
Direct | 702 Added 2.14% |
$23,419
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Scott Paterson
Director |
BUY
Grant, award, or other acquisition
|
Direct | 771 Added 0.28% |
$25,721
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Gordon Crawford
Director |
BUY
Grant, award, or other acquisition
|
Direct | 917 Added 0.44% |
$30,591
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Morley Koffman
Director |
BUY
Grant, award, or other acquisition
|
Direct | 576 Added 0.69% |
$19,215
$33.36 p/Share
|
Apr 01
2015 |
|
LGF-B
|
Harald Ludwig
Director |
BUY
Grant, award, or other acquisition
|
Direct | 263 Added 0.2% |
$8,774
$33.36 p/Share
|
Apr 01
2015 |
|
ORCL
|
Mark V Hurd
Chief Executive Officer |
SELL
Open market or private sale
|
Direct | 375,000 Reduced 99.73% |
$16,091,250
$42.91 p/Share
|
Apr 01
2015 |